Last edition
News about "immunoglobulin A nephropathy "
Bayer Files Japan Application to Expand Finerenone Use in Non-Diabetic CKD
Bayer’s Japan filing, backed by Phase III FIND-CKD data showing slower kidney function decline and a 23 percent reduction in cardiovascular-kidney events, seeks to expand finerenone’s potential role in treating adults with non-diabetic CKD and addressing a significant unmet medical need.
Immunoglobulin A Nephropathy | 31/08/2026 | By News Bureau
Novartis Gets FDA Accelerated Approval for Vanrafia
Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring the reduction of proteinuria at 36 weeks compared to placebo1. It has not been established whether Vanrafia slows kidney function decline in patients with IgAN.
Immunoglobulin A Nephropathy | 03/04/2025 | By Aishwarya | 412
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy